全文获取类型
收费全文 | 1706747篇 |
免费 | 128202篇 |
国内免费 | 4919篇 |
专业分类
耳鼻咽喉 | 21855篇 |
儿科学 | 55947篇 |
妇产科学 | 46354篇 |
基础医学 | 242710篇 |
口腔科学 | 48946篇 |
临床医学 | 153217篇 |
内科学 | 335245篇 |
皮肤病学 | 38840篇 |
神经病学 | 131766篇 |
特种医学 | 64338篇 |
外国民族医学 | 245篇 |
外科学 | 258690篇 |
综合类 | 42028篇 |
现状与发展 | 11篇 |
一般理论 | 533篇 |
预防医学 | 125327篇 |
眼科学 | 40443篇 |
药学 | 125359篇 |
31篇 | |
中国医学 | 5646篇 |
肿瘤学 | 102337篇 |
出版年
2021年 | 13664篇 |
2019年 | 14105篇 |
2018年 | 20518篇 |
2017年 | 15811篇 |
2016年 | 17174篇 |
2015年 | 19734篇 |
2014年 | 27150篇 |
2013年 | 38908篇 |
2012年 | 54053篇 |
2011年 | 56869篇 |
2010年 | 33730篇 |
2009年 | 31520篇 |
2008年 | 52433篇 |
2007年 | 55607篇 |
2006年 | 55992篇 |
2005年 | 53159篇 |
2004年 | 51241篇 |
2003年 | 48698篇 |
2002年 | 46778篇 |
2001年 | 92117篇 |
2000年 | 93855篇 |
1999年 | 77198篇 |
1998年 | 19846篇 |
1997年 | 17402篇 |
1996年 | 17486篇 |
1995年 | 16818篇 |
1994年 | 15376篇 |
1993年 | 14127篇 |
1992年 | 57428篇 |
1991年 | 55309篇 |
1990年 | 53004篇 |
1989年 | 50783篇 |
1988年 | 46160篇 |
1987年 | 44952篇 |
1986年 | 42239篇 |
1985年 | 39998篇 |
1984年 | 29354篇 |
1983年 | 24912篇 |
1982年 | 13900篇 |
1979年 | 25531篇 |
1978年 | 17575篇 |
1977年 | 14906篇 |
1976年 | 13875篇 |
1975年 | 14565篇 |
1974年 | 17631篇 |
1973年 | 16945篇 |
1972年 | 15673篇 |
1971年 | 14453篇 |
1970年 | 13431篇 |
1969年 | 12517篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
11.
Kara S. Tanaka MD Veronica R. Andaya BA Steven W. Thorpe MD Kenneth R. Gundle MD James B. Hayden MD Yee-Cheen Duong MD Raffi S. Avedian MD David G. Mohler MD Lee J. Morse MD Melissa N. Zimel MD Richard J. O'Donnell MD Andrew Fang MD Robert Lor Randall MD Tina H. Tran BS Christin New BA Rosanna L. Wustrack MD other members of Study Group FORCE 《Journal of surgical oncology》2023,127(1):148-158
12.
Comprehensive evidence regarding the treatment of non-anaemic iron deficiency in patients undergoing valvular heart surgery is lacking. This study aimed to investigate the association between non-anaemic iron deficiency and postoperative outcomes in these patients. We retrospectively analysed 321 patients of which 180 (56%) had iron deficiency (defined as serum ferritin < 100 ng.ml-1 or < 300 ng.ml-1 with transferrin saturation < 20%). While the iron-deficient group had lower pre-operative haemoglobin levels than the non-iron deficient group (median (IQR [range]) 134 (127–141 [120–172]) g.l-1, 143 (133–150 [120–179]) g.l-1, p = 0.001), there was no between-group difference in allogeneic red blood cell transfusion. Median (IQR [range]) days alive and out of hospital at postoperative day 90 was 1 day shorter in the iron-deficient group (80 (77–82 [9–85]) days vs. 81 (79–83 [0–85]) days, p = 0.026). In multivariable analysis, only cardiopulmonary bypass duration (p = 0.032) and intra-operative allogeneic red blood cell transfusion (p = 0.011) were significantly associated with reduced days alive and out of hospital at postoperative day 90. Iron deficiency did not exert any adverse influence on secondary outcomes except length of hospital stay. Our findings indicate that non-anaemic iron deficiency alone is not associated with adverse effects in patients undergoing valvular heart surgery when it does not translate into an increased risk of allogeneic transfusion. 相似文献
13.
14.
Clinical & Experimental Metastasis - 相似文献
15.
16.
17.
Adjuvant irradiation is the standard treatment after breast conservative surgery. Normofractionated regimen with an overall treatment time of 5 to 6 weeks is often considered as a limiting factor for irradiation compliance. In order to answer this issue, moderate and more recently extreme hypofractionated protocols appeared. We report here oncological outcomes and toxicity of hypofractionated breast irradiation. After defining the frame of moderate and extreme hypofractionated breast irradiations based on overall treatment time, patient selection criteria were listed. According to their levels of proof, the results of moderate and extreme hypofractionated breast irradiation were analysed. Overall treatment time for moderate hypofractionated breast irradiation ranged from 3 to 4 weeks, while for extreme hypofractionated breast irradiation, it was less than 1 week. For moderate hypofractionated breast irradiation, whole breast irradiation was currently performed with or without lymph node irradiation. Moderate hypofractionated breast irradiation has proven to be as safe and as efficient as normofractionated breast irradiation with level IA evidence. For extreme hypofractionated breast irradiation, phase III randomized trials confirmed that accelerated partial breast irradiation was non-inferior in terms of local control compared to normofractionated whole breast irradiation (with external beam radiation therapy and multicatheter brachytherapy), with similar acute and late toxicity. While the use of intraoperative breast irradiation remains under debate, new very accelerated partial breast irradiation (overall treatment time not exceeding 2 days) protocols emerged with encouraging results. Accelerated partial breast irradiation is warranted for extreme hypofractionated breast irradiation and is indicated for low-risk breast cancers. Moderate and extreme hypofractionated breast irradiation regimens are validated and can be routinely proposed according to patient selection criteria. 相似文献
18.
中医药防治动脉粥样硬化的研究具有良好的实践基础和应用前景,治疗方法可归于四类,即活血化瘀、化痰调脂、痰瘀同治、扶正祛邪,研究者辨证施治,多在临床上取得了满意的疗效。目前研究仍存在一些亟待解决的问题:首先,中医药防治动脉粥样硬化临床研究重复性差,缺乏大样本、多中心、高质量的临床研究及系统深入的实验研究;其次,对专家经验方及中药复方研究不够深入,临床药效物质基础不明确,缺乏对其作用机制的深入挖掘;再次,目前的研究不够系统和全面,主要集中在对动脉粥样硬化的形成和发展过程的研究,对斑块易损性研究相对较少。针对上述问题,今后应加强中医药治疗动脉粥样硬化的基础及临床研究,为治疗提供更加明确的理论依据和临床证据;同时,建立具有中医特色的研究模式,以中医宏观辨证理论为指导,利用现代医学技术,参考现代中药药理实验结果选药组方,扩大辨证选药思路,加强对中药方剂配伍规律的研究,以及对其有效成分的分离提取、鉴定和作用机制研究,并将传统组方理论与针对发病机制的对病治疗相结合,多角度、多层次探索中医药的作用机理。此外,应不断深入探索动脉粥样硬化的发病机制,并结合细胞工程、分子生物学及基因科学,积极研究中医药的药效学基础和机制。 相似文献
19.
20.